Jpmorgan Chase & CO Renovo Rx, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Renovo Rx, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 40 shares of RNXT stock, worth $41. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40Holding current value
$41% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding RNXT
# of Institutions
21Shares Held
2MCall Options Held
0Put Options Held
0-
Bank Of The West975KShares$1 Million0.27% of portfolio
-
Geode Capital Management, LLC Boston, MA236KShares$242,8200.0% of portfolio
-
Adar1 Capital Management, LLC Austin, TX197KShares$203,1670.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA141KShares$145,7310.0% of portfolio
-
Nixon Peabody Trust CO Boston, MA97.2KShares$100,0790.01% of portfolio
About RenovoRx, Inc.
- Ticker RNXT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 9,066,860
- Market Cap $9.34M
- Description
- RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, In...